跳至主要内容
临床试验/NCT00828477
NCT00828477已完成4 期

Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Bp Consulting, Inc1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
25
试验地点
1
主要终点
Tolerability of study medication

研究概览

简要总结

The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

详细描述

Open label, single armed, cross over controlled study to evaluate comfort and IOP (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes) scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • > 18 years old, either gender or any race.
  • Diagnosis of open-angle glaucoma or ocular hypertension requiring laser trabeculoplasty.
  • Completion of written and informed consent/authorization prior to any study related procedures.
  • Able to follow study protocol and likely to complete study schedule.

排除标准

  • Known sensitivity to NSAIDs.
  • History of neovascular or ocular inflammatory disease.
  • Current use of topical or systemic anti-inflammatory medications.
  • Females of childbearing potential.

研究组 & 干预措施

1

Active Comparator

Xibrom (bromfenac)

干预措施: Xibrom (Drug)

2

Active Comparator

Nevanac (nepafenac)

干预措施: Nevanac (Drug)

结局指标

主要结局

Tolerability of study medication

时间窗: 28 days

次要结局

  • Intraocular pressure changes(28 days)
  • Visual Acuity(28 days)

研究者

申办方类型
Network

研究点 (1)

Loading locations...

相似试验